SCHEDULE 13D: Major Shareholder Li Haixiang and Epoch Partner Investments Disclose 45.7% Stake in IceCure Medical Ltd.

Li Haixiang and Epoch Partner Investments Limited have disclosed a significant beneficial ownership of 45.7% in IceCure Medical Ltd., holding 25,846,597 ordinary shares for investment purposes.

Summary

• Li Haixiang and Epoch Partner Investments Limited (the "Reporting Persons") have filed a Schedule 13D disclosing their beneficial ownership in IceCure Medical Ltd.
• The Reporting Persons collectively own 25,846,597 Ordinary Shares of IceCure Medical Ltd.
• This ownership represents approximately 45.7% of the Issuer's outstanding Ordinary Shares, based on 56,568,999 shares outstanding as of December 31, 2024.
• The aggregate purchase price for these shares was approximately $39.97 million, funded by working capital.
• The shares are held for investment purposes, and Mr. Li Haixiang, as the sole director of Epoch, also serves as a director of IceCure Medical Ltd., indicating potential influence over corporate activities.

Sentiment

Score: 6

Explanation: The filing is largely neutral as it discloses an existing, significant ownership stake. The positive aspect is the strong commitment from a major shareholder who is also a director, aligning interests. The potential for influence is noted as a risk, but it's a standard aspect of such large ownership. No new negative operational or financial news is presented.

Positives

• A significant, long-term investment by a major shareholder (Li Haixiang and Epoch Partner Investments Limited) demonstrates strong confidence in IceCure Medical Ltd.
• The substantial stake of 45.7% by a director (Li Haixiang) aligns the interests of a key insider with those of other shareholders.

Negatives

• The filing primarily discloses an existing ownership stake and does not indicate any new capital infusion into the company.
• The document does not provide any new operational or financial performance updates for IceCure Medical Ltd.

Risks

• The significant ownership stake (45.7%) by the Reporting Persons, coupled with Mr. Li Haixiang's position as a director, grants them substantial influence over the corporate activities of IceCure Medical Ltd., which could include decisions related to mergers, asset sales, changes in management, or other strategic matters.
• The Reporting Persons reserve the right to formulate future plans and proposals regarding their investment, which could potentially lead to changes in the company's direction or structure.

Future Outlook

The Reporting Persons hold their securities for investment purposes and reserve the right to formulate plans and/or proposals and to take actions with respect to their investment in IceCure Medical Ltd., including potential corporate activities such as mergers, asset sales, or changes in management.

Management Comments

• "The Reporting Persons hold all securities of the Issuer for investment purposes."
• "The Reporting Persons reserve the right to formulate plans and/or proposals and to take such actions with respect to its investment in the Issuer, including any or all of the actions set forth in clauses (a) through (j) of Item 4 of Schedule 13D."

Industry Context

This filing pertains to a significant ownership stake in IceCure Medical Ltd., a company operating in the medical sector (implied by 'Medical Ltd.'). While the filing itself does not provide specific industry trends, the substantial investment by a single entity suggests a belief in the long-term prospects of the company within its market segment. The medical device industry is characterized by innovation, regulatory hurdles, and market adoption challenges, which large, committed shareholders can help navigate.

Comparison to Industry Standards

• This document is a Schedule 13D filing disclosing beneficial ownership and does not contain financial or operational results that can be directly compared to industry standards or specific comparable companies/projects. Its purpose is to inform the market about a significant ownership stake and the intentions of the reporting persons.

Related Party Transactions

• Epoch Partner Investments Limited, whose sole director is Mr. Li Haixiang (also a director of IceCure Medical Ltd.), acquired shares of IceCure Medical Ltd. through Securities Purchase Agreements on February 7, 2015, January 26, 2021, and December 21, 2022.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant shareholder's stake and intentions, potentially influencing investor confidence and perception of control. The large, committed stake by a director could be seen positively.
• Management/Board: The Reporting Persons, particularly Mr. Li Haixiang as a director, have substantial influence over corporate activities, potentially impacting strategic decisions and governance.

Next Steps

• The Reporting Persons may formulate future plans or proposals regarding their investment in IceCure Medical Ltd.
• The Reporting Persons may take actions related to their investment, including those outlined in Item 4 of Schedule 13D (e.g., changes in control, mergers, asset sales).

Key Dates

Keywords

IceCure Medical Ltd., Schedule 13D, Beneficial Ownership, Li Haixiang, Epoch Partner Investments, Shareholder Stake, Investment Filing, Corporate Governance, SEC Filing, Medical Devices